Trial Profile
18F-PD-L1 PET/CT to Predict Response to Nivolumab in Patients With NSCLC
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 17 Oct 2023 Planned End Date changed from 25 Dec 2022 to 30 Dec 2024.
- 17 Oct 2023 Planned primary completion date changed from 25 Dec 2022 to 30 Dec 2023.
- 07 Nov 2022 Planned End Date changed from 25 Oct 2021 to 25 Dec 2022.